Digipath (OTCMKTS:DIGP) versus NeoGenomics (NASDAQ:NEO) Financial Contrast

NeoGenomics (NASDAQ:NEO – Get Rating) and Digipath (OTCMKTS:DIGP – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

Institutional & Insider Ownership

88.2% of NeoGenomics shares are held by institutional investors. 1.0% of NeoGenomics shares are held by insiders. Comparatively, 10.8% of Digipath shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

NeoGenomics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Digipath has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.

Profitability

This table compares NeoGenomics and Digipath’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-28.30%	-9.15%	-5.31%
Digipath	-73.57%	N/A	-117.58%

Valuation and Earnings

This table compares NeoGenomics and Digipath’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$509.73 million	4.54	-$144.25 million	($1.16)	-15.64
Digipath	$2.70 million	0.21	-$2.06 million	($0.02)	-0.35

Digipath has lower revenue, but higher earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Digipath, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for NeoGenomics and Digipath, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	0	4	8	0	2.67
Digipath	0	0	0	0	N/A

NeoGenomics currently has a consensus price target of $19.33, suggesting a potential upside of 6.58%. Given NeoGenomics’ higher probable upside, equities research analysts clearly believe NeoGenomics is more favorable than Digipath.

Summary

NeoGenomics beats Digipath on 8 of the 13 factors compared between the two stocks.

About NeoGenomics

(Get Rating)

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients’ oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

About Digipath

(Get Rating)

DigiPath, Inc. is a service-oriented independent testing laboratory and data analytics company, which engages in the provision of cannabis testing, education, training, and news coverage. The company was founded by Todd Denkin on October 5, 2010 and is headquartered in Las Vegas, NV.